Achondroplasia (Dwarfism) — NDIS Support
Yes — Achondroplasia (Dwarfism) can qualify for NDIS support. Achondroplasia is on the NDIA’s List B — permanence is recognised, and you evidence the functional impact on daily life. Funding covers reasonable and necessary supports across daily living, therapy, social participation and capacity building.
Achondroplasia is the most common form of dwarfism, caused by a change in the FGFR3 gene that slows the growth of bone, particularly in the limbs, spine and base of the skull. It affects about 1 in 25,000 babies born in Australia. Characteristic features include short stature with shorter arms and…
Achondroplasia & the NDIS FAQs
- Is Achondroplasia eligible for the NDIS?
- Achondroplasia isn't automatically eligible, and short stature on its own doesn't qualify. Access depends on whether related, permanent impairments — such as chronic pain, mobility limits, spinal complications or reduced reach — substantially reduce your everyday functioning. Occupational-therapy and specialist…
- Does achondroplasia affect intelligence or life expectancy?
- No. Intelligence is typically in the normal range, and life expectancy is usually close to average. The main challenges are physical and medical, so careful monitoring — particularly of the spine, airway and hearing in childhood — is important to prevent or manage complications early.
- What health issues need monitoring in achondroplasia?
- Key areas include narrowing of the spinal canal (which can compress nerves or the spinal cord), obstructive sleep apnoea, recurrent ear infections and hearing loss, bowed legs, and chronic back and joint pain. In infancy, the skull base and airway are watched closely. Regular reviews help catch and manage these issues.
- What everyday supports help most with achondroplasia?
- Practical supports make the biggest difference: home and vehicle modifications, reaching aids and adapted controls, occupational therapy for daily-living tasks, and physiotherapy for joint and mobility care. Pain management supports long-term comfort and function, and support workers help with tasks made harder by…
- What is vosoritide?
- Vosoritide is a medicine that encourages new bone growth in children with achondroplasia who are still growing, and it was added to Australia's Pharmaceutical Benefits Scheme in 2023. It isn't suitable for everyone, and decisions about it are made with a specialist. It is a medical treatment and separate from NDIS…
Achondroplasia & the NDIS — practical guides
- Applying for the NDIS with Achondroplasia (Dwarfism)
- Assistive Technology for Achondroplasia (Dwarfism)
- Day Programs & Community Participation for Achondroplasia (Dwarfism)
- NDIS Funding & Budget for Achondroplasia (Dwarfism)
- Therapy & Allied Health for Achondroplasia (Dwarfism)
- Finding & Managing Support Workers for Achondroplasia (Dwarfism)
Related conditions
- Arthrogryposis and the NDIS
- Bardet-Biedl Syndrome and the NDIS
- CDKL5 Deficiency Disorder and the NDIS
- Cerebral Visual Impairment (CVI) and the NDIS
- Chiari Malformation and the NDIS
- Chronic Kidney Disease (End-Stage Renal) and the NDIS
- Coffin-Siris Syndrome and the NDIS
- Complex Regional Pain Syndrome (CRPS) and the NDIS
- Crohn's Disease & Inflammatory Bowel Disease and the NDIS
- Dissociative Identity Disorder and the NDIS
Sources
Reviewed by the Novida editorial team · last reviewed 2026-07-12. General information only — not medical advice.